Article
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
American journal of hematology - 1 Apr 2015
Strati Paolo, Kantarjian Hagop, Ravandi Farhad, Nazha Aziz, Borthakur Gautam, Daver Naval, Kadia Tapan, Estrov Zeev, Garcia-Manero Guillermo, Konopleva Marina, Rajkhowa Trivikram, Durand Menda, Andreeff Michael, Levis Mark, Cortes Jorge
Abstract excerpt
We investigated the combination of midostaurin and azacitidine (AZA) in patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). Patients received AZA 75 mg m(-2) on days 1-7 and midostaurin 25 mg bid (in cohort 1 of phase I) or 50 mg bid (in cohort 2 of Phase I an...
Topics
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
- Azacitidine
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans